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Background: Acute lymphoblastic leukemia (ALL) diagnosed within the first month of life is classified as congenital
ALL and has a significantly worse outcome than ALL diagnosed in older children. This suggests that congenital ALL
is a biologically different disease, and thus may be caused by a distinct set of mutations. To understand the somatic
and germline mutations contributing to congenital ALL, the protein-coding regions in the genome were captured
and whole-exome sequencing was employed for the identification of single-nucleotide variants and small insertion
and deletions in the germlines as well as the primary tumors of four patients with congenital ALL.
Methods: Exome sequencing was performed on Illumina GAIIx or HiSeq 2000 (Illumina, San Diego, California).
Reads were aligned to the human reference genome and the Genome Analysis Toolkit was used for variant calling.
An in-house developed Ensembl-based variant annotator was used to richly annotate each variant.
Results: There were 1–3 somatic, protein-damaging mutations per ALL, including a novel mutation in Sonic
Hedgehog. Additionally, there were many germline mutations in genes known to be associated with cancer
predisposition, as well as genes involved in DNA repair.
Conclusion: This study is the first to comprehensively characterize the germline and somatic mutational profile of
all protein-coding genes patients with congenital ALL. These findings identify potentially important therapeutic
targets, as well as insight into possible cancer predisposition genes.
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Acute lymphoblastic leukemia (ALL) is the most com-
mon type of cancer diagnosed in children. Congenital
ALL is a rare and aggressive subtype of ALL defined as
diagnosis within the first month of life. A recent study
of 30 patients with congenital ALL treated on the
Interfant-99 protocol reported a 2-year event-free sur-
vival of 20% despite intensive chemotherapy [1]. This is
significantly worse than the 5-year event-free survival of
older children with ALL, which approaches 80% [2]. Al-
though the 11q23 rearrangement is the most common
cytogenetic abnormality in congenital and infant ALL
[3], studies demonstrate that this rearrangement is not* Correspondence: vchang@mednet.ucla.edu
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reproduction in any medium, provided the orsufficient for leukemogenesis [4,5] and does not entirely
explain the aggressiveness of ALL in this population of
patients [6-8].
These data demonstrate that congenital ALL is a bio-
logically different disease, and therefore may be caused
by a distinct set of mutations in ALL blast cells that
differ from blasts from older patients. Whole-exome se-
quencing can be used to characterize the majority of
amino acid encoding base positions of the genome.
When applied to cancer, this method can identify som-
atic mutations that may contribute to leukemogenesis,
as well as germline mutations that may reveal cancer
predisposition genes [9-12]. In this paper, we report
whole-exome sequencing on four paired tumor-normal
samples from patients with congenital ALL and fully
characterize the germline and somatic mutations. In
addition, healthy parents of one patient were alsoLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Our results demonstrate that there are very few somatic
mutations in cALL and that there are potential drug-
gable targets that may provide new therapeutic options
to improve outcomes.
Methods
The UCLA Institutional Review Board approved this
study, which was carried out in compliance with the
Helsinki Declaration, and all participants, or parents of
participants, provided written informed consent before
samples were collected.
Patient characteristics
We collected peripheral blood at diagnosis and remis-
sion bone marrow from four patients with congenital
ALL (Table 1). The institutional review board reviewed
and approved this study.
DNA extraction and sequencing
Tumor genomic DNA was extracted from peripheral
blood at diagnosis and normal genomic DNA was
extracted from remission bone marrow using QIAmp
DNA Minikit (Qiagen, Valencia, California). Genomic
DNA was enriched for coding exons using Sure Se-
lect Human All Exon for sample 1, and Human All
Exon 50Mb kits for samples 2–4 (Agilent, Santa
Clara, California). Sample 1 was sequenced on one
full lane of the Illumina Genome Analyzer IIx as
76x76 base paired-end reads as well as one full lane of
the HiSeq2000 as 50x50 base paired-end reads and
reads were merged for downstream analysis (Illumina,
San Diego, California). Leukemia sample numbers 2
through 4 and parents of sample 1 were sequenced on
one full lane of the HiSeq2000 as 100x100 base pair,
paired-end reads, while the germlines of samples 2–4
were sequenced on one full lane of the HiSeq2000 as
50x50 base pair, paired-end reads.
Variant calling and filtration
Sequence reads were aligned to the human reference
genome build 37, using Novoalign (novocraft.com).
Post-processing of reads was performed using Samtools
(samtools.sf.net) and Picard (picard.sf.net) for removal of
PCR duplicates, merging, and indexing [13].Table 1 Sample characteristics
ID Translocation % peripheral blasts at diagnosis
Sample 1 t(4;11) 92%
Sample 2 t(4;11) 94%
Sample 3 t(11;19) 80%
Sample 4 Negative 95%The Genome Analysis Toolkit (GATK) was used for
recalibration of base quality, variant calling, filtration
and evaluation [14,15]. Quality scores generated by the
sequencer were recalibrated by analyzing the covariation
among reported.
Quality score, position within the read, dinucleotide,
and probability of a reference mismatch. Local realign-
ment around small insertions and deletions (indels) was
performed, using GATK's indel realigner to minimize
the number of mismatching bases across all reads.
Statistically significant non-reference variants, single nu-
cleotide substitutions (SNS) and small indels were iden-
tified using the GATK UnifiedGenotyper. The GATK
VariantAnnotator annotated each variant with various
statistics, including allele balance, depth of coverage,
strand balance, and multiple quality metrics. These
statistics were then used in an adaptive error model to
identify likely false positive SNSs, using the GATK
VariantQualityScoreRealibrator (VQSR). Single nucleo-
tide substitutions with a low VQSR score were filtered
out, leaving a set of likely true variants. Hard filtering
was applied to indels and only passing indels were used
for subsequent analyses.
An in-house program based on the Ensembl database
(http://www.ensembl.org) was used to further annotate var-
iants with gene, transcript, and protein identifiers, conserva-
tion, tissue-specific expression, reference and alternate allele






Variants were filtered out if they were in non-coding
regions, resulted in synonymous amino acid changes, or
were predicted to have a benign change in protein func-
tion by Polyphen (http://genetics.bwh.harvard.edu/pph)
or Sift (http://sift.jcvi.org). Variants were classified as
rare if alternate allele frequencies were less than 1%.
Nonsynonymous, protein-damaging, and rare germline
variants were intersected with known germline muta-
tions that predispose to cancer syndromes, found in
Cosmic [16]. Germline variants were also intersected
with known DNA repair genes [17]. Germline variants
in sample 1 were cross-checked with the parents’ se-
quence data to identify inherited versus de novo muta-
tions. All germline and somatic variants at the last step
of filtering were manually visualized using Integrated
Genomics Viewer [18].
Somatic analysis
Mutations were classified as somatic if they were rare and
found in the tumor sample only with no evidence in the
Table 2 Alignment and coverage statistics by sample
Total Reads Total Mapped % Covered at 20x Average Coverage % PCR duplicates
Sample 1 tumor 304,589,893 271,320,952 92% 210x 7.6
Sample 1 germline 295,105,503 263,056,333 90% 199x 8.9
Sample 1 mother 195,514,828 193,745,082 86% 147x 32.5
Sample 1 father 203,906,150 202,199,642 85% 145x 36.2
Sample 2 tumor 204,158,706 142,291,992 84% 141x 7.7
Sample 2 germline 243,212,434 220,803,923 82% 107x 14.5
Sample 3 tumor 185,947,244 127,115,774 83% 128x 7.6
Sample 3 germline 252,335,878 204,463,822 83% 111x 16.0
Sample 4 tumor 214,824,644 157,010,833 85% 149x 7.8
Sample 4 germline 239,034,182 215,730,577 83% 108x 15.7
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reference and non-reference reads and p-value <1x10-6 was
used as the cut-off for significance. Somatic mutations
found in sample 1 were cross-checked with the parents’ se-
quence data to ensure they were indeed somatic and not
alleles missed in the germline. Three somatic variants were
excluded because they were present as non-reference reads
in one or both parents.Polymerase chain reaction and capillary sequencing
The SHH mutation in Sample 1, FLT3 mutation in
Sample 3, and DMBT-1 mutation in Sample 4 were vali-
dated using PCR and capillary sequencing. All primers
for mutations were designed using Primer3Plus (http://
www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.
cgi) and ordered from Integrated DNA Technologies
(Coralville, IA). Capillary sequencing was performed on
Biosystems 3730 Capillary DNA Analyzer (Life Tech-
nologies, Carlsbad, CA). Raw and analyzed sequence
results were visualized on Sequence Scanner v1.0 (Life
Technologies, Carlsbad, CA). There was not sufficientFigure 1 Number of single nucleotide substitutions per sample.DNA for Sample 2 to validate variants with PCR and ca-
pillary sequencing.Results
Alignment and coverage statistics
The total number of reads per sample ranged from
about 185,000,000-304,000,000 (Table 2). Sixty eight to
ninety nine percent of reads aligned to the reference
human genome and 87-94% of reads were covered at a
minimum 20 times. The overall average coverage ranged
from 107-210x.
Each sample had 19,210-23,859 total single nucleotide
substitutions. Greater than 93% of these were single nu-
cleotide polymorphisms found in dbSNP132, with 99.8%
concordance with the alternate allele found in dbSNP132.
There were 791–1,462 novel single nucleotide variants per
sample after removing polymorphisms found in dbSNP132
(Figure 1). Each sample had 1,222-1,716 total small indels.
After removing polymorphisms found in dbSNP132, each
sample had 688–943 novel indels (Figure 2). Variants were
further prioritized if they were nonsynonymous, predicted
Figure 2 Number of small insertions and deletions by sample.
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general control population (Figure 3).
Germline mutations
There were 2–6 germline mutations in each sample that
were also in the Cosmic list of genes that have previously
been associated with cancer predisposition [16]. Addition-
ally, there were 7–13 germline mutations in each sample in
genes that are known DNA repair genes. When comparing
the congenital ALL samples with 28 control exomes from
children without cancer sequenced in the same laboratory
and analyzed with the same workflow, there were noFigure 3 Number of variants by filtration step.statistically significant differences between mean numbers
of mutations that overlapped with Cosmic germline genes
or DNA repair genes (Table 3). Due to the small numbers
of patients in each group, it was not possible to directly
compare specific germline mutations within the cALL
group and the control group.
Somatic mutations
There were 1–3 nonsynonymous, protein-damaging,
rare variants found in each tumor sample with no evi-
dence in the corresponding germline data using Fisher’s
Exact p-value <1x10-6 on the reference and non-
reference reads (Table 4). All these mutations were het-
erozygous. The two somatic mutations in sample 1 were
homozygous reference in both parents.
Discussion
Although there has been significant progress in overall
survival for children with ALL, newborns with congeni-
tal ALL continue to have poor prognoses despite inten-
sive therapy. There is a need to identify new therapeutic
targets in congenital ALL to rationally design treatment
regimens that will produce sustained remissions with
less toxicity. Additionally, understanding the molecular
basis for congenital ALL may lead to novel insights intoTable 3 Comparison of mean overlap with Cosmic
germline genes and DNA repair genes in patients with
cALL and children without cancer
Mean overlap with
Cosmic
Mean overlap with DNA
repair genes
4 cALL patients 5.18 9.50
28 control exomes 3.92 11.17
p-value 0.32 0.57
P-values calculated with Student’s t-test.
Table 4 Nonsynonymous, protein-damaging, rare somatic
mutations with p-value <1x10-6




Sample 1 1:166039478 FAM78B */Y .
7:155599125 SHH* G/S Deleterious, Probably-
damaging










Sample 4 10:124380869 DMBT1* H/N Tolerated, Possibly-
damaging
*Validated with PCR and capillary sequencing.
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dromes. This study is the first to comprehensively
characterize the somatic and germline mutational profile
of all protein-coding genes in four tumor-normal paired
samples from patients born with congenital ALL.
Sample 1 had a somatic mutation in SHH, which has not
previously been reported in ALL. The Hedgehog pathway
is known to have a role in normal B-lymphocyte develop-
ment and use of Hedgehog pathway inhibitors leads to
decreased self-renewal potential [19]. The G143S mutation
found in Sample 1 lies in a critical signaling region of the
SHH protein that interacts with the SHH receptor, Patched
(PTCH). Association of SHH with PTCH releases the in-
hibitory effect of PTCH on Smoothened (SMO), which
allows for the propagation of SHH signals to activate tran-
scription factors including GLI-1, 2, and 3 [20]. It is pos-
sible that this mutation has an activating effect on SHH
that leads to dysregulation of downstream target genes.
Two of the four samples had somatic mutations in
FLT3. Point mutations and internal tandem duplications
in FLT3 are known to be driver mutations in acute mye-
logenous leukemia (AML) but are also enriched in infant
ALL [21]. Multiple oral FLT3 inhibitors have been tested
in Phase 1 and 2 trials as single agents, as well as in
combination with other chemotherapy agents for treat-
ment of AML [22-25] with promising results. This study
identified that single nucleotide substitutions in FLT3
are recurrent in ALL and infants with ALL might benefit
from treatment with FLT3 inhibitors.
Conclusion
This is the first study to perform exome sequencing on
paired tumor and normal samples from patients with con-
genital ALL. Three of the four tumor samples had somatic
mutations in genes that are druggable targets. Germlineanalyses did not reveal any clear set of cancer predispos-
ition genes but a larger number of samples will need to be
sequenced in order to delineate the role of DNA repair
genes and known germline cancer predisposition genes, as
well as to identify novel cancer predisposition genes.
As the cost of next-generation sequencing continues
to decrease, patients and physicians will routinely en-
counter opportunities to supplement traditional morph-
ology, flow cytometry, and cytogenetics tests with a
base-pair level resolution of all variants in the exome as
well as whole genome. High-throughput functional
assays to validate the effect of all candidate driver muta-
tions will be needed to fully take advantage of this level
of mutational profiling. Additionally, inherited or de
novo mutations in patients’ germlines will continue to
expand currently known cancer predisposition syn-
dromes and may eventually lead to approaches for earl-
ier cancer detection and even cancer prevention.
Competing interests
The authors declare no financial or non-financial competing interests.
Authors’ contributions
VC carried out the sequence data analysis and drafted the manuscript. KS
and SN participated in the design and coordination of the study, and helped
to draft the manuscript. GB and KS recruited the patients. All authors read
and approved the final manuscript.
Authors’ information
Authors Kathleen M Sakamoto and Stanley F Nelson are both co-senior
authors.
Acknowledgements
We would like to express our deepest appreciation to our patients and their
families. We also thank Rongqing Guo and Traci Toy for excellent technical
assistance. This project was supported by Parents against Leukemia, Evelyn
Grace Foundation, and the National Center for Research Resources, Grant
UL1RR033176, which is now at the National Center for Advancing
Translational Sciences, Grant UL1TR000124. The content is solely the
responsibility of the authors and does not necessarily represent the official
views of the NIH. V.C. was supported on the T32 Developmental Hematology
grant (T32HL086345), K12 Child Health Research Career Development Award
(2K12HD034610-16) and by the American Society of Hematology.
Author details
1Department of Pediatrics, Division of Hematology-Oncology, University of
California, Los Angeles, 10833 Le Conte Ave., MDCC A2-410, Los Angeles, CA
90095, USA. 2Woman and Child Health Department, University of Padova, Via
Giustiniani, 335128, PADOVA, Italy. 3Department of Pediatrics, Division of
Hematology/Oncology, Stanford University School of Medicine, CCSR-1215C,
269 Campus Drive, Stanford, CA 94305-5162, USA. 4Department of Human
Genetics, Pathology and Laboratory Medicine, and Psychiatry, University of
California, Los Angeles, 695 Charles E. Young Drive South, Los Angeles, CA
90095, USA.
Received: 21 September 2012 Accepted: 30 January 2013
Published: 4 February 2013
References
1. van der Linden MH, Valsecchi MG, De Lorenzo P, Moricke A, Janka G,
Leblanc TM, Felice M, Biondi A, Campbell M, Hann I, Rubnitz JE, Stary J,
Szczepanski T, Vora A, Ferster A, Hovi L, Silverman LB, Pieters R: Outcome of
congenital acute lymphoblastic leukemia treated on the Interfant-99
protocol. Blood 2009, 114(18):3764–3768.
2. Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN,
Hunger SP, Devidas M: Long-term results of the children's cancer group
Chang et al. BMC Cancer 2013, 13:55 Page 6 of 6
http://www.biomedcentral.com/1471-2407/13/55studies for childhood acute lymphoblastic leukemia 1983–2002: a
Children's Oncology Group Report. Leukemia 2010, 24(2):285–297.
3. Rubnitz JE, Link MP, Shuster JJ, Carroll AJ, Hakami N, Frankel LS, Pullen DJ,
Cleary ML: Frequency and prognostic significance of HRX
rearrangements in infant acute lymphoblastic leukemia: a Pediatric
Oncology Group study. Blood 1994, 84(2):570–573.
4. Montes R, Ayllon V, Gutierrez-Aranda I, Prat I, Hernandez-Lamas MC, Ponce
L, Bresolin S, Te Kronnie G, Greaves M, Bueno C, Menendez P: Enforced
expression of MLL-AF4 fusion in cord blood CD34+ cells enhances the
hematopoietic repopulating cell function and clonogenic potential but is
not sufficient to initiate leukemia. Blood 2011, 117(18):4746–4758.
5. Bursen A, Schwabe K, Ruster B, Henschler R, Ruthardt M, Dingermann T,
Marschalek R: The AF4.MLL fusion protein is capable of inducing ALL in
mice without requirement of MLL.AF4. Blood 2010, 115(17):3570–3579.
6. Pui CH, Frankel LS, Carroll AJ, Raimondi SC, Shuster JJ, Head DR, Crist WM,
Land VJ, Pullen DJ, Steuber CP, et al: Clinical characteristics and treatment
outcome of childhood acute lymphoblastic leukemia with the t(4;11)
(q21;q23): a collaborative study of 40 cases. Blood 1991, 77(3):440–447.
7. Satake N, Maseki N, Nishiyama M, Kobayashi H, Sakurai M, Inaba H, Katano
N, Horikoshi Y, Eguchi H, Miyake M, Seto M, Kaneko Y: Chromosome
abnormalities and MLL rearrangements in acute myeloid leukemia of
infants. Leukemia 1999, 13(7):1013–1017.
8. Pui CH, Raimondi SC, Srivastava DK, Tong X, Behm FG, Razzouk B, Rubnitz JE,
Sandlund JT, Evans WE, Ribeiro R: Prognostic factors in infants with acute
myeloid leukemia. Leukemia 2000, 14(4):684–687.
9. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, Shi JY, Zhu YM, Tang L, Zhang XW,
Liang WX, Mi JQ, Song HD, Li KQ, Chen Z, Chen SJ: Exome sequencing
identifies somatic mutations of DNA methyltransferase gene DNMT3A in
acute monocytic leukemia. Nat Genet 2011, 43(4):309–315.
10. Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W,
Spanhol-Rosseto A, Klein HU, Dugas M, Schindela S, Trifonov V, Schnittger S,
Haferlach C, Bassan R, Wells VA, Spinelli O, Chan J, Rossi R, Baldoni S, De
Carolis L, Goetze K, Serve H, Peceny R, Kreuzer KA, Oruzio D, Specchia G, Di
Raimondo F, Fabbiano F, Sborgia M, Liso A, Farinelli L, Rambaldi A,
Pasqualucci L, Rabadan R, Haferlach T, Falini B: Whole-exome sequencing
identifies somatic mutations of BCOR in acute myeloid leukemia with
normal karyotype. Blood 2011, 118(23):6153–6163.
11. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, Landa I, Leandro-Garcia LJ,
Leton R, Honrado E, Ramos-Medina R, Caronia D, Pita G, Gomez-Grana A, de
Cubas AA, Inglada-Perez L, Maliszewska A, Taschin E, Bobisse S, Pica G, Loli
P, Hernandez-Lavado R, Diaz JA, Gomez-Morales M, Gonzalez-Neira A,
Roncador G, Rodriguez-Antona C, Benitez J, Mannelli M, Opocher G,
Robledo M, Cascon A: Exome sequencing identifies MAX mutations as a
cause of hereditary pheochromocytoma. Nat Genet 2011, 43(7):663–667.
12. Saarinen S, Aavikko M, Aittomaki K, Launonen V, Lehtonen R, Franssila K,
Lehtonen HJ, Kaasinen E, Broderick P, Tarkkanen J, Bain BJ, Bauduer F, Unal A,
Swerdlow AJ, Cooke R, Makinen MJ, Houlston R, Vahteristo P, Aaltonen LA:
Exome sequencing reveals germline NPAT mutation as a candidate risk
factor for Hodgkin lymphoma. Blood 2011, 118(3):493–498.
13. Homer N, Nelson SF: Improved variant discovery through local re-
alignment of short-read next-generation sequencing data using SRMA.
Genome Biol 2010, 11(10):R99.
14. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A,
Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA: The Genome
Analysis Toolkit: a MapReduce framework for analyzing next-generation
DNA sequencing data. Genome Res 2010, 20(9):1297–1303.
15. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA,
del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ, Kernytsky AM,
Sivachenko AY, Cibulskis K, Gabriel SB, Altshuler D, Daly MJ: A framework for
variation discovery and genotyping using next-generation DNA sequencing
data. Nat Genet 2011, 43(5):491–498.
16. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A,
Teague J, Futreal PA, Stratton MR, Wooster R: The COSMIC (Catalogue of
Somatic Mutations in Cancer) database and website. Br J Cancer 2004,
91(2):355–358.
17. Wood RD, Mitchell M, Lindahl T: Human DNA repair genes, 2005. Mutat Res
2005, 577(1–2):275–283. Sep 4.
18. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G,
Mesirov JP: Integrative genomics viewer. Nat Biotechnol 2011, 29(1):24–26.
19. Lin TL, Wang QH, Brown P, Peacock C, Merchant AA, Brennan S, Jones E,
McGovern K, Watkins DN, Sakamoto KM, Matsui W: Self-renewal of acutelymphocytic leukemia cells is limited by the Hedgehog pathway
inhibitors cyclopamine and IPI-926. PLoS One 2010, 5(12):e15262.
20. Taipale J, Cooper MK, Maiti T, Beachy PA: Patched acts catalytically to
suppress the activity of Smoothened. Nature 2002, 418(6900):892–897.
21. Taketani T, Taki T, Sugita K, Furuichi Y, Ishii E, Hanada R, Tsuchida M,
Ida K, Hayashi Y: FLT3 mutations in the activation loop of tyrosine
kinase domain are frequently found in infant ALL with MLL
rearrangements and pediatric ALL with hyperdiploidy. Blood 2004,
103(3):1085–1088.
22. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM,
Dauses T, Allebach J, Small D: Single-agent CEP-701, a novel FLT3
inhibitor, shows biologic and clinical activity in patients with relapsed or
refractory acute myeloid leukemia. Blood 2004, 103(10):3669–3676.
23. DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB,
Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT,
Druker BJ, Heinrich MC: Phase 1 clinical results with tandutinib (MLN518),
a novel FLT3 antagonist, in patients with acute myelogenous leukemia
or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and
pharmacodynamics. Blood 2006, 108(12):3674–3681.
24. Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J,
Kantarjian HM, Deangelo DJ, Huntsman-Labed A, Dutreix C, Del Corral A,
Giles F: Phase IB study of the FLT3 kinase inhibitor midostaurin with
chemotherapy in younger newly diagnosed adult patients with acute
myeloid leukemia. Leukemia 2012, 26(9):2061–2068.
25. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W,
Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG,
Griffin JD: Patients with acute myeloid leukemia and an activating
mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase
inhibitor, PKC412. Blood 2005, 105(1):54–60.
doi:10.1186/1471-2407-13-55
Cite this article as: Chang et al.: Identification of somatic and germline
mutations using whole exome sequencing of congenital acute
lymphoblastic leukemia. BMC Cancer 2013 13:55.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
